Celgene (CELG): Raising Estimates - Cantor

Cantor Fitzgerald analyst, Mara Goldstein, reiterated her Overweight rating on shares of Celgene (NASDAQ: CELG) and believes that the growing pipeline is not yet priced into the valuation.

CELG has already provided 2016 and 2017 guidance, essentially preannouncing a strong 4Q16 setting guidance well ahead of street (Factset) consensus.

The new EPS forecasts are $5.94 for 2016 versus the prior $5.93 and $7.22 for 2017 versus $7.05.

No change to the price target of $159.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $117.08 yesterday.

You May Also Be Interested In

• CFRA Upgrades Infosys Technologies (INFY) to Buy
• Jefferies Upgrades Reckitt Benckiser (RKT:LN) (RBGLY) to Hold
• Bank OZK (OZK) PT Raised to $47 at Keefe, Bruyette & Woods